Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Coagulopathy

Coagulopathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Coagulopathy

5 trials tracked for Coagulopathy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 370 citations.

5Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 2 Other / NA 2
  1. Phase 3 Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Completed · 370 cited
  2. Phase 4 Octaplas Pediatric Plasma Replacement Trial Completed · 14 cited
  3. Phase 3 Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants Completed
  4. N/A Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication Completed
  5. N/A Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Coagulopathy: what the trials found

Octaplas was evaluated for its impact on hemostatic parameters, specifically the International Normalized Ratio (INR). Clinical data showed that 25 out of 50 participants experienced clinically significant changes in INR following administration 1.

Pennsaid demonstrated a reduction in the International Normalized Ratio (INR) from baseline to week 4, with reported values of 0.63, 0.09, and 0.00 across the study cohort 3.

ART-123 was evaluated for its impact on mortality and organ dysfunction. There was no statistically significant difference in 28-day all-cause mortality between groups (p=0.318) 2. Mean event-free and alive days to measure resolution of organ dysfunction ranged from 14.5 to 20.2 across various cohorts 2.

Recent results — preliminary, needs further review

  • Fibrinolytic Therapy showed no statistically significant difference in ICU free days (p=0.61) or chest tube days (p=0.84) 4.
  • ROTEM was utilized as an intervention, though specific outcome data is not provided in the trial summary 5.

For the clinician treating this condition

  • Octaplas is associated with clinically significant changes in INR in patients with coagulopathy 1.
  • Pennsaid results in a decrease in International Normalized Ratio (INR) from baseline to week 4 3.
  • ART-123 does not show a statistically significant impact on 28-day all-cause mortality compared to control 2.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
TEG-ROTEM guided transfusion may lower death and bleeding in cardiac surgery
Hematology Sys. Review
TEG-ROTEM guided transfusion may lower death and bleeding in cardiac surgery New blood management tools may lower death risk during heart surgery, but proof is weak
A systematic review finds TEG-ROTEM guided transfusion may reduce mortality and bleeding in elective cardiac surgery, but evidence certainty…
A review suggests new blood tests could reduce death and bleeding during heart surgery, yet the evidence remains very uncertain and mostly c…
Cochrane May 18, 2026
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Hematology Meta-analysis
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
This systematic review and meta-analysis evaluated 37,459 patients to assess the association between various biomarkers and clinical factors…
Blood markers like glycocalyx degradation and low fibrinogen can predict deadly clotting in sepsis patients early, potentially saving lives …
Apr 14, 2026